Healthcare

Financing the frontier of healthcare.

Enabling groundbreaking discoveries.

  • Best-in-Class Research

    Our independent, actionable insights power the hundreds of company and industry reports we publish each year.

  • Transactional Expertise

    We’ve successfully raised billions of dollars for healthcare innovators worldwide since 2015.

  • Extensive Network

    Our robust relationships can be leveraged through hundreds of hosted and sponsored events.

  • Highly Specialized

    Our institutional equities team is made up of professionals averaging decades of focused experience.

Get in Touch

Early-Stage Fundraising

We work with early-stage companies to advance their vision and ensure longevity.

Chardan’s private financing capabilities include company formation, seed financing, initial rounds of pre-IPO funding, as well as bridge and mezzanine financing.  We provide private companies access to a robust network of fundamental healthcare institutional investors, venture funds and Chardan’s unique distribution network of family offices to raise the capital they need to get off the ground.

Chardan has led landmark private transactions for cutting-edge private companies, including Forge Biologics’ $120 million series B financing and PassageBio’s $115.5 million Series A financing and $110 million Series B financing, ReCode Therapeutics’ $80 million Series A financing, and Taysha Gene Therapies $30 million Seed round.

$ 690 million
capital raised for private companies since 2015
Reach out to discuss your transaction

IPO & Follow-On

Chardan provides guidance and execution services for healthcare companies seeking to access the capital markets to support their growth strategies. Our highly experienced equity capital markets team connects companies to a large network of investors and strategics. Additionally, we spend considerable time assisting companies with positioning, materials and broader market color.

Our team holds a highly successful record with key roles on numerous marquis biotech IPOs including AveXis, Moderna, Passage Bio and Achilles.

$ 9.5 billion
raised for healthcare companies since 2005
Reach out to discuss your transaction

SPACs

Chardan has been a leader in SPACs since 2004, and in 2018, pioneered the use-case of SPACs for biotech companies. We have since developed an industry-leading healthcare SPAC practice acting as sponsor, underwriter and M&A advisor.

For innovative private or non-US listed healthcare companies, we identify if the SPAC instrument is the right way for their company to get public, identify potential SPAC partners, advise on structure and assist if there is an additional capital requirement via a PIPE or bridge financing.

For SPAC sponsors looking to combine with healthcare companies, our domain expertise and access to deal flow is unparalleled. Chardan is an ideal partner to help you get a successful deal closed. 

Learn more about our healthcare SPAC practice.

17
Healthcare SPACs underwritten since 2005
Reach out to discuss your transaction

M&A and Reverse Mergers

When navigating key M&A transactions in your company’s lifecycle, Chardan is your most powerful advisor. We work with public and private healthcare companies providing in-depth advice and strategic guidance to help you evaluate, plan, and execute your most important directives while focusing on value creation. Our services include business combination advisory, mergers, acquisitions, restructurings and joint ventures. We pride ourselves on flawless execution resulting in long term client success.

12
Healthcare M&A Transactions since 2005
Reach out to discuss your transaction

Research and Events

Best-in-Class Research:

Chardan healthcare analysts look to cover names in areas that have strong potential to outperform healthcare in the next 5-10 years. We are known for our independent voice, actionable insights, intellectual honesty and scientific grounding, evident in our industry-leading frameworks, company notes and weekly pieces.

Our expertise spans areas such as cell therapy and regenerative medicine, immuno-oncology, vaccines, infectious diseases, hematology, lipids, ophthalmology, NASH, neurodegenerative disorders, rare diseases, and more. For example, in genetic medicines, our team’s thought leadership has been exemplified by academic publications, various speakerships, and alpha generation in our Genetic Medicines Alpha Portfolios (GMAPs). Our team publishes the only dedicated weekly sector newsletter, entitled “Viral News in Genetic Medicines”.

*Stat data from 2019-2021

Events: Our influence extends beyond printed research through hundreds of hosted and sponsored events, where we bring together the best companies, investors, and other industry innovators around the world. Extensive corporate access opportunities including large annual conferences, partnered academic and industry symposiums and a robust network of leading industry pioneers.

We help public and private companies target and attract the right audiences—and then hone your outreach strategy based on our timely, detailed analysis. Along the way, we manage event-day logistics to ensure the success of every event. Tap into our global network to meet the investors, companies, or industry thought leaders who will help take your vision to the next level.

Event Types

  • Non-Deal Roadshow
  • KOL Events
  • Leadership Calls/Webinars
  • Conferences
  • Fieldtrips

See select replays from our events on Chardan's YouTube channel.

6
Annual Conferences dedicated to healthcare companies
Request an invitation to our events

Meet our healthcare banking leadership.

Meet our healthcare research team.

Thank You!

We've received your information, and we're processing your request.

Get In Touch

17 State Street
Suite 2130
New York, NY 10004

One East Putnam Ave, 4th Fl. Greenwich, CT 06830

+1 646-465-9000

info@chardan.com

All fields required
SUBMIT